19 unknown. 19 Phase 2, 3 Phase 1, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 19 | Unknown 19 |
| Phase 1 | 3 | Unknown 3 |
| Phase 3 | 3 | Unknown 3 |
Follow Acute Ischemic Stroke: new trials by email Literature Review of Acute Ischemic Stroke trials Research Report on Acute Ischemic Stroke
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| BXOS110 Injection in the Treatment of Acute Ischaemic Stroke high-dose BXOS110, low-dose BXOS110, Placebo - Acute Ischemic Stroke | Phase 2 | Unknown | Biocells (Beijing) Biotech Co.,Ltd | 300 | 2024-02-07 | 2024-03-21 |
| EFfects of Y-6 SUblingual Tablets foR PaTients With AcUte Ischemic StRokE (FUTURE) Low-dose Y-6 sublingual tablets, High-dose Y-6 sublingual tablets, Low-dose Cilostazol - Acute Ischemic Stroke, Large Vessel Occlusion | Phase 2 | Unknown | Beijing Tiantan Hospital | 300 | 2023-11-01 | 2023-11-18 |
| Sodium Valproate in Patients With Acute Ischemic Stroke Sodium valproate, Normal saline - Acute Ischemic Stroke | Phase 2 | Unknown | RenJi Hospital | 40 | 2023-09-01 | 2024-02-21 |
| Cilostazol Dexborneol Versus Placebo for Microcirculation Dysfunction After Reperfusion Therapy in Patients With Acute Ischemic Stroke With Large Vessel Occlusion Y-6 sublingual tablets, Placebo tablets of Y-6 sublingual tablet - Acute Ischemic Stroke, Reperfusion | Phase 2 | Unknown | Beijing Tiantan Hospital | 120 | 2023-06-05 | 2023-09-28 |
| Study of the KPCXM18 Injection for Treatment of Acute Ischemic Stroke The KPCXM18 injection, Placebo - Acute Ischemic Stroke | Phase 2 | Unknown | Kunming Pharmaceuticals, Inc. | 240 | 2023-03-01 | 2023-02-28 |
| Dengzhanxixin Injection for Acute Ischemic Stroke Receiving Reperfusion Therapy Dengzhanxixin Injection, Placebo injection - Acute Ischemic Stroke | Phase 2 | Unknown | Beijing Tiantan Hospital | 240 | 2022-09-30 | 2023-01-26 |
| A Study of XY03-EA Tablets in the Treatment of Acute Ischemic Stroke XY03-EA, XY03-EA Placebo - Acute Ischemic Stroke | Phase 2 | Unknown | Shijiazhuang Yiling Pharmaceutical Co. Ltd | 420 | 2022-09-24 | 2023-06-22 |
| Platelet Function in Patients With Ischemic Stroke Treated With Anti-thrombotic or Thrombolytic Thrombolytic Agent - Acute Ischemic Stroke | Phase 1 / Phase 2 | Unknown | Baylor College of Medicine | 30 | 2022-02-18 | 2022-06-10 |
| A Study Evaluating the Safety and Efficacy of Tirofiban in Combination With Alteplase in Acute Ischemic Stroke Tirofiban 0.05 MG/ML, 0.9% sodium chloride solution - Acute Ischemic Stroke | Phase 2 | Unknown | GrandPharma (China) Co., Ltd. | 266 | 2021-12-09 | 2023-02-23 |
| Combination of the Immune Modulator Dimethyl Fumarate With Alteplase in Acute Ischemic Stroke Dimethyl Fumarate - Acute Ischemic Stroke | Phase 1 / Phase 2 | Unknown | Xuanwu Hospital, Beijing | 50 | 2021-12-01 | 2022-06-06 |
| Thrombolysis Treated With TNK-tPA in Acute Ischemic Stroke Patients （3T Stroke-II） Alteplase, Tenecteplase - Acute Ischemic Stroke | Phase 2 | Unknown | Beijing Tiantan Hospital | 225 | 2021-05-02 | 2022-03-31 |
| A PhaseⅡ of Injection for Recombinant Human Tissue Plasminogen Kinase Derivative in Treatment of Acute Ischemic Stroke. r-PA, Alteplase for Injection - Acute Ischemic Stroke | Phase 2 | Unknown | Angde Biotech Pharmaceutical Co., Ltd. | 180 | 2019-07-20 | 2019-07-22 |
| Trial of EXenatide in Acute Ischaemic Stroke Exenatide Injection - Acute Ischemic Stroke | Phase 2 | Unknown | Neuroscience Trials Australia | 350 | 2017-11-23 | 2021-09-14 |
| Clinical Trial to Evaluate the Efficacy and Safety of JPI-289 in Patients With Acute Ischemic Stroke JPI-289 Low-dose, JPI-289 High-dose, Placebo - Acute Ischemic Stroke | Phase 2 | Unknown | Jeil Pharmaceutical Co., Ltd. | 110 | 2016-12-09 | 2019-11-18 |
| BEnefits of Stroke Treatment Delivered Using a Mobile Stroke Unit Mobile Stroke Unit Management - Acute Ischemic Stroke | Phase 2 / Phase 3 | Unknown | Memorial Hermann Health System | 1038 | 2014-08-01 | 2023-03-17 |
| Efficacy and Safety of Mildronate for Acute Ischemic Stroke infusion of mildronate, placebo, aspirin - Acute Ischemic Stroke | Phase 2 | Unknown | Xijing Hospital | 240 | 2013-01-01 | 2013-02-27 |
| Study to Assess the Safety and Efficacy of THR-18 When Administered to Patients Suffering Acute Ischemic Stroke and Treated With Tissue Plasminogen Activator (tPA) THR-18, Placebo - Acute Ischemic Stroke | Phase 1 / Phase 2 | Unknown | Thrombotech Ltd. | 22 | 2011-03-01 | 2010-12-03 |
| Effectiveness and Safety of Xiaoshuanchangrong (XSCR) Capsule for the Treatment of Patients Who Have Suffered From a Stroke XSCR capsule (Composed of Traditional Chinese Medicine Huangqi, Chuanxiong, Chishao, Danggui, Dilong, Taoren, Honghua.), Placebo - Acute Ischemic Stroke | Phase 2 / Phase 3 | Unknown | Fudan University | 130 | 2008-09-01 | 2010-05-28 |
| Effectiveness and Safety of Angongniuhuang Pill on Restoring Consciousness for Patients Who Have Suffered From a Stroke Angongniuhuang Pill, placebo - Stroke, Acute Ischemic Stroke | Phase 2 / Phase 3 | Unknown | Fudan University | 60 | 2010-05-28 |
Ischemic Stroke (19) · Stroke (5) · Edema (1)
Brain Diseases (19) · Cardiovascular Diseases (19) · Central Nervous System Diseases (19) · Cerebrovascular Disorders (19) · Nervous System Diseases (19) · Vascular Diseases (19) · Stroke (14) · Pathological Conditions, Signs and Symptoms (1) · Signs and Symptoms (1)
Tissue Plasminogen Activator (3) · Aspirin (1) · Cilostazol (1) · Dimethyl Fumarate (1) · Eptifibatide (1) · Exenatide (1) · Fibrinolytic Agents (1) · Honghua extract, Carthamus tinctorius (1) · Injections (1) · JPI-289 (1) · Saline Solution (1) · Sodium Chloride (1) · TNK-tissue plasminogen activator (1) · Tenecteplase (1) · Thrombectomy (1)
Beijing Tiantan Hospital (4) · Fudan University (2) · Angde Biotech Pharmaceutical Co., Ltd. (1) · Baylor College of Medicine (1) · Biocells (Beijing) Biotech Co.,Ltd (1) · GrandPharma (China) Co., Ltd. (1) · Jeil Pharmaceutical Co., Ltd. (1) · Kunming Pharmaceuticals, Inc. (1) · Memorial Hermann Health System (1) · Neuroscience Trials Australia (1) · RenJi Hospital (1) · Shijiazhuang Yiling Pharmaceutical Co. Ltd (1) · Thrombotech Ltd. (1) · Xijing Hospital (1) · Xuanwu Hospital, Beijing (1)
China (12) · United States (2) · Australia (1) · Finland (1) · Israel (1) · New Zealand (1) · South Korea (1)
Christopher Bladin (1) · Gang Zhao, MD (1) · James C Grotta, MD (1) · Jieqing Wan, Doctor (1) · Junwei Hao, PhD,MD (1) · Peiying Li, Doctor (1) · Ronen R. Leker, MD, FAHA (1) · Shuya Li (1) · Yi Zhu, MD (1) · Yilong Wang, PhD+MD (1) · Yilong Wang, PhD，MD (1) · Yongjun Wang, M.D. (1) · Yongjun Wang, MD (1) · Zhipeng Wang, Ph.D, MD (1)
PMID 16574919, PMID 19233036, PMID 20185783, PMID 20651267, PMID 22435369, PMID 23418571, PMID 25726502, PMID 28082671, PMID 28612680, PMID 28780236, PMID 29694815, PMID 29720439, PMID 32295510, PMID 33449944, PMID 34496173, PMID 38011235, PMID 38152962, PMID 40246318, PMID 41608799, PMID 42621146, PMID 9186381
2018 (1)